1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Orient EuroPharma Co., Ltd.

Orient EuroPharma Co., Ltd.

4120.TWO
Orient EuroPharma Co., Ltd.TW flagTaipei Exchange
47.40
TWD
-0.10
- -
4.11BMarket Cap
Orient EuroPharma Co., Ltd.
4120.TWO
(Taipei Exchange)

Recent

price

47.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
49.2
47.51
52.03
53.78
57.64
56.57
60.31
60.25
63.52
70.24
62.06
54.95
54.53
52.93
50.62
- -
53.13
Revenue per Share
3.42
2.09
2.67
5.84
2.26
2.57
5.41
5.29
2.84
2.86
2.3
1.39
-3.58
1.66
-3.27
- -
-6.56
Basic EPS, GAAP
-3.07
-1.96
2.42
-1.36
1.81
4.73
-1.31
2.66
0.31
0.56
4.3
-17.18
-9.91
-0.42
-2.55
- -
-5.56
Free Cash Flow per Basic Share
0.57
0.75
1.3
2.02
1.83
1.73
1.97
1.92
2.62
1.95
1.86
1.63
1
0.18
1.16
- -
1.06
Dividend per Share
18.93
19.6
20.37
26.34
24.1
24.77
28.13
30.85
30.6
30.34
30.32
27.07
21.39
25.05
28.43
- -
46.79
Book Value per Share
29.87
31.59
33.52
39.56
38.4
38
44.15
46.27
46.76
42.51
43.81
38.91
39.2
47.49
66.64
- -
84.43
Tangible Book Value per Share
81
86
87
87
87
87
87
87
87
87
87
87
87
87
87
- -
86
Basic Weighted Avg Shares
3,992
4,098
4,513
4,665
5,000
4,907
5,232
5,226
5,510
6,093
5,384
4,767
4,730
4,592
4,391
4,595
4,595
Sales/Revenue/Turnover
7.8
4.42
4.1
1.41
4.27
5.37
9.05
8.33
6.48
5.43
2.18
-2.06
-3.17
1.57
0.3
-6.5
-6.5
Operating Margin (%)
43
71
81
86
97
109
109
96
104
182
197
191
194
216
207
198
198
Depreciation Expense
278
181
232
507
196
223
470
459
247
248
199
120
-311
144
-284
-567
-567
Net Income, GAAP
27.86
46.38
30.55
0.89
43.64
33.74
17.77
36.42
60.1
62.53
57.23
12.35
- -
33.94
- -
- -
140.3
Effective Tax Rate (%)
6.96
4.41
5.14
10.86
3.92
4.55
8.98
8.78
4.48
4.06
3.7
2.52
-6.57
3.13
-6.47
-12.35
-12.35
Profit Margin (%)
1,101
1,279
1,191
1,744
1,693
1,549
2,202
1,798
2,251
1,769
1,888
693
392
515
668
1,383
1,383
Working Capital
141
236
156
323
234
320
766
372
723
851
988
1,899
2,439
2,203
1,698
1,233
1,233
LT Debt
2,494
2,780
2,992
3,517
3,418
3,384
3,916
4,098
4,142
3,812
3,905
3,453
3,444
4,162
5,824
7,354
7,354
Total Equity
7.44
2.87
3.7
1.72
2.98
4.27
8.36
5.38
2.63
2.14
0.82
-1.22
- -
0.54
- -
- -
- -
Return on Invested Capital (%)
12.29
8.79
10.69
18.56
7.95
9.64
14.56
13.25
7.44
7.15
5.51
3.11
- -
2.51
- -
- -
-3.34
Return on Capital (%)
19.45
11.2
13.41
25.01
8.96
10.53
20.47
17.93
9.26
9.37
7.58
4.83
-14.79
7.15
-12.24
-17.42
-17.42
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
1,989
1,689
2,037
LT Borrowings
1,203
862
925
LT Finance Leases
326
318
308
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
87
87
87
Market Capitalization
4,811
4,325
3,875

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
4,347
4,412
4,298
Cash, Cash Equivalents & STI
2,130
2,145
2,122
Accounts Receivable, Net
717
757
767
Inventories
1,219
1,167
1,086
Total Current Liabilities
3,125
2,668
2,915
Payables & Accruals
- -
- -
- -
ST Debt
1,989
1,689
2,037
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.11%
15.04%
26.25%
Free Cash Flow
22.36%
-1.12%
117.28%
Net Income, GAAP
-69.93%
-148.41%
99.83%
Sales/Revenue/Turnover
-0.4%
-2.98%
4.64%
Total Cash Common Dividend
43.29%
83.05%
0.07%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1,151
1,133
1,095
1,213
4,592
2024
1,104
1,086
1,067
1,134
4,391
2025
1,156
1,126
1,115
1,197
4,595

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.32
-2.18
-0.4
- -
1.66
2024
-1.04
-0.81
0.13
- -
-3.27
2025
-1.77
-0.53
-1.49
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.18
2024
- -
- -
0.99
- -
1.16
2025
- -
- -
1
- -
- -
Similar Companies
Zhejiang Garden Biopharmaceutical Co.,Ltd. (300401.SZ)
Gage Growth Corp. (GAEGF)
cbdMD, Inc. (YCBD-PA)
Tasly Pharmaceutical Group Co., Ltd (600535.SS)
NxGen Brands Inc. (NXGB)
iAnthus Capital Holdings, Inc. (IAN.CN)
Business
Orient EuroPharma Co., Ltd. (4120.TWO) is a multinational pharmaceutical company that develops, manufactures, markets, and distributes prescription medicines, nutritional care products, dermo-cosmetics, healthcare supplements, and innovative medical therapies across Asia-Pacific markets including Taiwan, Singapore, Malaysia, Hong Kong, Macau, the Philippines, mainland China, and Indonesia. Its prescription medicines encompass cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, oncology, and anti-cancer drugs sourced from international partners; nutrition and baby care offerings include goat milk formulas and nutritional supplements under the Karihome, Babecare, and Ostricare brands; dermo-cosmetics feature skincare products such as essences, creams, lotions, eye creams, and body treatments under AGLab, Bio-Oil, Buccotherm, ISISPHARMA, and Mister Baby brands; healthcare supplements target preventive medicine for aging populations; and innovative medical products involve R&D pipelines like Multikine for head and neck cancer, NC-6004 for chemotherapy, ASC-J9 for androgen degradation, and 2ccPA for osteoarthritis. Founded in 1982 and headquartered at 13F, No. 128, Sec. 6, Chengde Road, Taipei, Taiwan, the company listed on the Taipei Exchange in 2003 and operates subsidiaries including Orient Pharma for R&D and manufacturing, OP NanoPharma, and overseas entities in Southeast Asia and China. In recent developments, Orient EuroPharma, through affiliate Cyntec, signed an exclusive licensing agreement with Rakuten Medical in June 2025 for Alluminox platform-based photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines to expand its oncology portfolio; its subsidiary Orient Pharma plans an OTC market listing in late August 2025 following achievements in international certifications; and earlier partnerships include a 2024 commercial license for Trogarzo with Taimed Biologics in Taiwan and a 2023 license for oregovomab with OncoVent for ovarian cancer in the region.

Company News

APIChatGPT

  • globenewswire.com

    George Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient EuroPharma in Southeast Asia